These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32806997)

  • 1. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
    Ernest JP; Strydom N; Wang Q; Zhang N; Nuermberger E; Dartois V; Savic RM
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():495-516. PubMed ID: 32806997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
    Pienaar E; Linderman JJ; Kirschner DE
    PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
    Aguilar Diaz JM; Abulfathi AA; Te Brake LH; van Ingen J; Kuipers S; Magis-Escurra C; Raaijmakers J; Svensson EM; Boeree MJ
    Respiration; 2023; 102(2):83-100. PubMed ID: 36516792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antituberculosis drugs and new drug development.
    Agrawal S; Thomas NS; Dhanikula AB; Kaul CL; Panchagnula R
    Curr Opin Pulm Med; 2001 May; 7(3):142-7. PubMed ID: 11371769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
    Budha NR; Lee RE; Meibohm B
    Curr Med Chem; 2008; 15(8):809-25. PubMed ID: 18393850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced cellular systems to study tuberculosis treatment.
    Bielecka MK; Elkington P
    Curr Opin Pharmacol; 2018 Oct; 42():16-21. PubMed ID: 29990957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present and future of tuberculosis treatment.
    Bi K; Cao D; Ding C; Lu S; Lu H; Zhang G; Zhang W; Li L; Xu K; Li L; Zhang Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):657-668. PubMed ID: 36915970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antituberculosis drug resistance: practical solutions to practical problems.
    Tayler E
    J Med Microbiol; 1997 Jul; 46(7):531-3. PubMed ID: 9236735
    [No Abstract]   [Full Text] [Related]  

  • 18. Trends and challenges of multi-drug resistance in childhood tuberculosis.
    Zhuang Z; Sun L; Song X; Zhu H; Li L; Zhou X; Mi K
    Front Cell Infect Microbiol; 2023; 13():1183590. PubMed ID: 37333849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis treatment in children: The changing landscape.
    Huynh J; Thwaites G; Marais BJ; Schaaf HS
    Paediatr Respir Rev; 2020 Nov; 36():33-43. PubMed ID: 32241748
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.